Duality Advisers, LP Ultragenyx Pharmaceutical Inc. Transaction History

Duality Advisers, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 06, 2024	BUY	$43.02 - $53.69 $26,070 - $32,536	606 Added 1.54%	39,977 $1.87 Million
Q4 2023 Feb 01, 2024	BUY	$31.73 - $49.19 $391,326 - $606,660	12,333 Added 45.61%	39,371 $1.88 Million
Q3 2023 Nov 02, 2023	BUY	$34.92 - $46.66 $444,007 - $593,281	12,715 Added 88.77%	27,038 $963,000
Q2 2023 Jul 31, 2023	BUY	$37.35 - $52.15 $534,964 - $746,944	14,323 New	14,323 $660,000
Q3 2022 Nov 03, 2022	BUY	$39.96 - $66.14 $1.91 Million - $3.17 Million	47,879 New	47,879 $1.98 Million

325

85.5M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.14B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Duality Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Duality Advisers, LP with notifications on news.